Global Haematology and Coagulation Diagnostics Market Report, Size, Share and Forecast 2026-2033: Two Monopolies, One Tender

The discipline that files the most results and the smallest invoice

A complete blood count is the most frequently ordered laboratory test in medicine. It is also, per reportable result, one of the cheapest things a hospital buys. That combination — enormous volume, thin unit value — is what makes haematology and coagulation a different kind of market from the rest of in vitro diagnostics, and it is why the assumptions normally applied to diagnostics break here.

This report sizes the two fields together at USD 7,620 million in 2025, reaching USD 10,630 million in 2033 — a 4.25% CAGR, a 1.395x expansion and USD 3,010 million of absolute growth. Measured against the USD 108.0 billion IVD base carried in the head report of this cluster, the discipline is 7.06% of IVD value in 2025, falling to 6.30% by 2033. It is the only discipline in this cluster whose share of the market declines while its test volume grows faster than the market's.

Three findings organise everything that follows.

First: the field cannot be unbundled, and that is a price mechanism, not a technical detail

A six-part differential is produced by a closed system. The reagent, the optics, the algorithm that classifies a scattergram and the reference intervals the result is reported against come from one vendor and are validated together. There is no equivalent of the open chemistry channel, where a laboratory can buy a buffer from one supplier and a substrate from another. The consequence: 87.72% of this discipline's value attributes to named vendors, against 48.9% in clinical chemistry. Concentration and attributability are the same variable, read from two ends.

That is precisely what makes it a procurement target. A market where the buyer cannot substitute the reagent is a market where the only lever left is administered price.

Second: two administered prices, moving at once

In the United States, the preliminary CY 2027 Clinical Laboratory Fee Schedule cuts the complete blood count — code 85025, 36 million Medicare tests a year — from USD 7.77 to USD 6.89, a 11.3% reduction in the weighted median and a cumulative 35% below its 2018 level. In China, the Anhui provincial alliance ran the country's first volume-based procurement for coagulation reagents in January 2023: six coagulation items, 22 bidders, 16 selected, an average combined reduction of 40.16% and a maximum of 49.59%. Two documents, two continents, two very different numbers, one mechanism.

Third: the vendor disclosures sort themselves by geography, not by product

Sysmex's fiscal year to March 2026 is the cleanest natural experiment in the cluster. Group net sales fell 1.7%, to JPY 500,006 million, while operating profit fell 40.8%, to JPY 51,831 million, and operating margin collapsed from 17.2% to 10.4%. Inside that: China fell 24.2%, Japan fell 13.5%, the Americas grew 6.2% and EMEA grew 12.6%. Same products, same reagents, same service model. The only variable that moved was the price regime the products were sold into.

Werfen gives the counter-reading. Europe's haemostasis specialist grew organically 3.3% in 2025 to EUR 2,131 million; excluding Asia, organically 6%, with North America up 8%, Latin America up 10% and Eastern Europe, Middle East and Africa up 7%. Asia-Pacific fell 10.9%. Again: not the product. The market.

What this report measures

In scope: automated haematology analysers and their reagents, controls and calibrators (three-part through six-part differential, reticulocyte and body-fluid modes, digital morphology); automated and semi-automated coagulation analysers and their reagents (routine screening, D-dimer and fibrin degradation products, antithrombin and anti-Xa, thrombophilia and factor assays, von Willebrand and platelet-function testing, heparin-induced thrombocytopenia); and point-of-care haemostasis testing (activated clotting time, whole-blood INR, viscoelastic testing).

Out of scope, and deliberately: blood gas and electrolyte testing, transfusion immunohematology and donor screening (a distinct discipline built on a different regulatory frame), flow cytometry as a standalone instrument category, molecular haematology — BCR-ABL, JAK2, NPM1 — which belongs to the molecular cluster and is covered by the NGS and PCR reports, and haemostasis pharmaceuticals. Adjacency without double counting.

Market snapshot, 2025–2033

The two fields, and why they diverge

The discipline is two markets wearing one name, and they are moving in opposite directions inside the same forecast.

Haemostasis contributes 57.1% of the discipline's entire 2033 increment — USD 1,718 million of USD 3,010 million — from 42.91% of the 2025 base. Haematology grows its test volume faster (4.17% against 3.91%) and its revenue more slowly (3.31% against 5.42%). That inversion is the report's central structural argument: in haematology, volume is the problem, because volume is what gets tendered; in haemostasis, menu is the answer, because a D-dimer or an anti-Xa assay is a new line on a requisition rather than a cheaper version of an old one.

Decomposed into price and volume, haematology's realised revenue per result falls from USD 1.500 to USD 1.404 across the window — −6.4% over eight years — against clinical chemistry's −10.3% in the companion report. Haemostasis moves the other way: from USD 2.555 to USD 2.867 per result, +12.2%, as the mix shifts from PT and APTT toward D-dimer, anti-Xa and viscoelastic testing. Net across the discipline, revenue per result is almost exactly flat: +1.24% over eight years, a 0.15% CAGR. Flat is not stable. Flat is two contrary movements cancelling.

Base construction: what the vendors' own numbers will and will not support

The level is built bottom-up from disclosed vendor revenue and participant field estimates. No published aggregate was used to set it.

The residual is the finding. Every other report in this cluster carries a residual between 33% and 51%, because the named vendors could not fill the market and the unlisted middle had to be stated rather than invented. Here it is 12.28%. That is not better research; it is a structural fact about the field. In chemistry anyone can make a buffer; in haematology nobody can make a six-part differential without the vendor's reagent, algorithm and reference intervals. A market with a 12.3% residual is a market with no unlisted middle — which is exactly the condition that invites administered pricing.

The reconciliation that does not reconcile

Sysmex publishes two numbers that cannot both be right, and the gap is clean.

Its Integrated Report 2025 puts the global haematology field at USD 4,300 million (2024, own estimate) and its own share at 54.6%, ranked first. At 54.6% of USD 4,300 million, Sysmex's haematology revenue should be USD 2,348 million. Its disclosed haematology revenue for the year to March 2026 is JPY 299,407 million — USD 2,023 million at JPY 148/USD.

The shortfall is USD 325 million, or 13.8%. Read it one way and the market is 13.8% smaller than published (USD 3,705 million); read it the other and the share is 13.8% lower than published (47.0%). The two readings are arithmetically identical, and neither can be dismissed. This report uses USD 4,350 million for 2025 haematology — the published figure rolled forward — and treats the 13.8% as an explicit uncertainty band on the base rather than a resolved question. Any analyst quoting a haematology market size, including this one, is quoting a number whose only public derivation contradicts itself by 13.8%.

The same discipline applied to haemostasis produces a cleaner answer. Sysmex claims the number one position there too, but its own footnote discloses that this ranking "includes sales through alliances" — its instruments reach the market substantially under the Siemens Healthineers brand. Sysmex's disclosed hemostasis revenue of USD 489 million is 15.0% of a USD 3,270 million field, which cannot be a standalone first place. Werfen's attributed USD 1,200 million is 36.7%. On revenue, the haemostasis leader is Werfen, and the field's leader holds barely more than a third of it. Haematology has a monopoly. Haemostasis does not.

The tender that priced the discipline

Anhui province completed China's first volume-based procurement for coagulation and cardiac-marker IVD reagents in January 2023, and the design matters more than the headline. Bidders self-declared products onto a provincial procurement list. The ceiling was set not by a government formula but by the volume-weighted average of what Anhui hospitals had actually paid on the provincial platform the previous year. Bidders then competed on the size of their reduction against that ceiling, and 90% of the prior year's platform volume was committed as first-year purchase volume.

The result on the coagulation six: 22 bidders, 16 selected, an average combined reduction of 40.16%, a maximum of 49.59%. On the cardiac three: 26 bidders, 17 selected, an average of 57.35%, a maximum of 80%. Combined annual procurement savings were put at RMB 87.09 million. The mechanism is not a price negotiation. It is a price discovery exercise in which the state obtains the disclosure the market had been withholding.

Three disclosures then confirm it was the price and not the demand.

• Sysmex attributes its China RHQ decline of 24.2% — segment sales JPY 89,269 million — to "policies to curtail medical expenses," naming "hematology instruments and reagents, as well as hemostasis reagents." Its overseas hemostasis reagent sales fell while overseas haematology reagent sales rose. Same reagent categories, different tender coverage.
• Werfen grew 6% organically everywhere except Asia, and states that the industry "faced a widespread adjustment within the In-Vitro Diagnostics market in China." Asia-Pacific −10.9%.
• Mindray, the domestic challenger, saw international revenue rise 7.40% to RMB 17,650 million and domestic revenue fall 22.97% to RMB 15,632 million. Its IVD line fell 9.41% to RMB 12,241 million. It names immunoassay, chemistry and coagulation as the three core businesses it intends to double domestic share in within three years — a target that only makes sense if the price reset also cleared out competitors.

Mindray is the important one. Volume-based procurement is designed to favour domestic scale, and Mindray grew share in a shrinking domestic market. The discipline is not losing China; it is losing the China price. Those are different forecasts.

Two administered prices

There is a detail in the CMS publication that is specific to this report. Its results-by-category table names six categories — chemistry (387 codes, −16%), molecular pathology (211, −22%), genomic sequencing (42, −23%), microbiology (224, −19.3%), proprietary laboratory analysis (151, −2.4%) and immunology (205, −19.3%). Haematology is not one of them. The complete blood count, the second-highest-volume code in the entire schedule at 36 million Medicare tests, sits inside a category summary that does not name its own field. The largest-volume test in American medicine is priced in an accounting bucket.

The phase-in is the other half. The Consolidated Appropriations Act, 2026 amended the statute so that no test may be cut more than 15% a year from 2027 through 2029. ACLA's reading of the preliminary file counted 775 tests taking the full 15% in year one, and put the cumulative 2027–2029 reduction in Medicare Part B laboratory payments at about USD 3.3 billion against a payment system of roughly USD 9 billion a year. That is the deferral mechanism: a code facing a 35% gap is not protected by a 15% cap, it is merely scheduled.

Regional structure, 2025 and 2033

North America and Europe hold 56.56% of value in 2025 and lose 3.2 percentage points by 2033 while remaining over half the market. The two fastest-growing regions — Latin America at 7.09% and the Middle East and Africa at 6.72% — together add 1.9 points of share. Japan is the slowest at 2.22%, and its decline is visible in Sysmex's own disclosure: domestic sales fell 13.5% to JPY 58,603 million, with the domestic sales ratio down 1.6 points to 11.7%. A mature market with a shrinking population and a fee schedule that has already absorbed its cuts does not grow.

Product and technology structure

Reagents, controls and calibrators are 66.8% of the market in 2025 and 68.9% by 2033. Instruments are 20.9% falling to 19.0%. That ratio is the whole commercial logic: the analyser is placed, sometimes at cost, and the reagent stream is the annuity. It is also why a 40% reagent cut is a 40% cut to the business and a 5% cut to the invoice a hospital sends its payor. Werfen's own framing of the model is explicit — capital sales of analysers drive "an installed base of recurring high-margin reagent and consumable revenue."

End-market structure

Hospital central laboratories carry 61.02% of value. The commercial and reference segment grows fastest of the three large ones at 4.75%, because consolidation in that segment concentrates volume onto fewer, larger analyser decisions — a reference network buying a track is a single procurement covering dozens of hospitals' worth of tests.

Forecast, 2025–2033

The path is not straight, and the reason is timing rather than trend. 2026 carries the full anniversary of the Chinese reset with no offsetting recovery; 2027 is the first year the American fee schedule cut lands, at the same time as the Anhui precedent either spreads to further provinces or does not. The slight acceleration in 2032–2033 reflects the point at which the tendered base has been reset low enough that further cuts stop producing savings, and volume growth becomes the only variable left.

Sensitivities

The asymmetry is modest — 56 basis points either side of base — and that is the point. This discipline's forecast is not sensitive to technology adoption or to a single product cycle. It is sensitive to whether two governments continue to cut administered prices, and to nothing else at comparable magnitude.

Competitive snapshot

Editorial analysis on this market

Two companion pieces examine the mechanisms this report quantifies. The clinical chemistry and urinalysis report carries the companion price document analysis, and the same fee schedule reset that cuts the complete blood count by 11.3% cuts 387 chemistry codes by 16%. The immunoassay report establishes the method this report uses to separate a price effect from a demand effect, by holding volume and revenue from the same disclosure against each other.

For the discipline this report sits underneath, see the Global In Vitro Diagnostics market report, which carries the USD 108.0 billion base and the discipline split this report reconciles to. For the service layer that operates these analysers, see the clinical laboratory services report; for the near-patient setting where whole-blood coagulation testing is displacing the central lab, the point-of-care testing report; and for the tissue-based discipline that shares the same referral pathway, the histopathology report.

Sources

All figures in this report are drawn from primary documents. No market-research competitor material is cited, quoted or used to set any level.

• Sysmex Corporation — Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2026 (14 May 2026)
• Sysmex Corporation — Integrated Report 2025, field market size and share table
• Sysmex Corporation — Net Sales by Destination, Business and Product Type, FY2022/3–FY2026/3
• Werfen — Werfen reaches EUR 2.1 billion in sales and bolsters operational resilience (9 April 2026)
• Werfen — Annual Review 2025
• Werfen — ACL TOP Family 70 Series commercialisation in North America (31 March 2025)
• ARCHIMED — ARCHIMED Diagnostics acquires Stago (29 April 2026)
• Danaher Corporation — Fourth Quarter and Full Year 2025 Results (28 January 2026)
• Abbott Laboratories — Fourth-Quarter and Full-Year 2025 Results (22 January 2026)
• Centers for Medicare & Medicaid Services — Preliminary CY 2027 Medicare Clinical Laboratory Fee Schedule Payment Rates (21 September 2026)
• American Clinical Laboratory Association — Comments on Preliminary CY 2027 Medicare CLFS Payment Rates (20 October 2026)
• People's Daily, Anhui — Anhui province completes China's first coagulation and cardiac-marker IVD reagent volume-based procurement (20 January 2023)
• Shenzhen Mindray Bio-Medical Electronics — 2025 annual results briefing (31 March 2026)

About the method

70% secondary, 30% primary. The secondary layer is the disclosure set above: audited annual results, statutory fee schedules, provincial procurement notices and regulatory filings, all read directly rather than summarised.

The primary layer is 47 depth interviews across 13 markets with laboratory directors, haematology section leads, transfusion service managers, procurement officers and IVD channel partners; 29 open-ended interviews conducted around tender cycles in the Chinese provincial and Gulf Cooperation Council procurement markets; a 176-respondent structured survey of laboratory managers fielded across the same 13 markets on analyser replacement intent, menu expansion and reagent price expectations; and structured observation at four conferences — the International Society on Thrombosis and Haemostasis congress, the International Society for Laboratory Hematology symposium, the American Association for Clinical Chemistry annual meeting and the Chinese Laboratory Medicine Congress.

The primary layer is used for mechanism only. Every market level, share, growth rate and forecast in this report derives from the secondary layer or from arithmetic performed on it. No primary interview or survey response carries a figure. The interview counts, market coverage and respondent numbers above are stated so that they can be reconciled against programme records; they are not offered as a source for any number in the tables.

Where a published participant estimate and a disclosed revenue contradicted each other, both are shown and the contradiction is stated rather than resolved — see the 13.8% haematology reconciliation in the base construction section. Where a ranking cannot be supported on revenue, it is attributed to its actual basis — Sysmex's number one claim in haemostasis is alliance-inclusive, by its own footnote.

All arithmetic — CAGRs, shares, per-result decomposition, sensitivity paths — was computed deterministically and is reproducible from the tables above. Currency conversions use JPY 148/USD, EUR 1.13/USD and RMB 7.20/USD throughout — the same basis as every other report in this cluster.

Further reading: Global IVD Reagents and Consumables Market, 2026–2033 measures the layer this discipline attributes most cleanly to. Haematology and coagulation reagents are USD 5,880 million, 7.50% of the layer, growing 4.25% — the only product class in which the instrument lock is absolute, which is why this discipline's residual is 12.28% and the layer's is 51.24%.

Articles on this market

Two companion analyses are published against this report. The Complete Blood Count Is the Second-Most-Ordered Test in America and Its Category Does Not Exist examines the preliminary CY 2027 fee schedule and why haematology has no category in CMS's own results table. Sysmex's Own Numbers Disagree by Thirteen Point Eight Per Cent on the Size of the Market It Leads works through the reconciliation carried in the base construction section above.

Table of Contents

1. Market Definition and Scope
2. Executive Summary
3. Market Size and Forecast, 2025–2033
4. The Two Fields: Haematology and Haemostasis
5. Competitive Landscape
6. Value Chain and Revenue Model
7. Technology and Innovation
8. Investment Activity
9. Market Risk
10. Regulatory Landscape
11. Regional Analysis
12. End-Market Analysis
13. Research Methodology and Sources

Competitive Landscape

Competitive Landscape

This is the most concentrated discipline in in vitro diagnostics, and the concentration is measurable before any share table is drawn. Ten named vendors account for USD 6,684 million of a USD 7,620 million market — 87.72%. The residual is USD 936 million, or 12.28%. In clinical chemistry, the comparable residual is 51.1%. Both figures are computed the same way from the same kind of disclosure, and the difference is not analytical quality. It is a fact about the product.

A chemistry reagent is a formulation. A haematology result is a number produced by a specific instrument using that instrument’s reagent, interpreted against that instrument’s scattergram algorithm and reported against reference intervals the vendor validated. The buyer cannot substitute one component. Where substitution is impossible, revenue attributes cleanly to a short list of vendors — and where revenue attributes cleanly, a procurement authority can see exactly whom it is buying from and what they are charging.

Haematology: one leader, and a claim its own revenue contradicts

Sysmex is the haematology leader. Its Integrated Report puts the global field at USD 4,300 million and its own share at 54.6%, ranked first. Its disclosed haematology revenue for the year to March 2026 is JPY 299,407 million — USD 2,023 million at JPY 148/USD — which is 46.5% of the USD 4,350 million field used in this report and 13.8% below what a 54.6% share implies.

No analyst can resolve that from outside the company. What can be said is that the two figures are incompatible in exactly one direction and by exactly one magnitude, and that the market presented here sits between them. The concentration itself is not in doubt: the next three competitors together — Beckman Coulter at an estimated USD 610 million, Abbott at USD 470 million and Horiba at USD 250 million — hold less than Sysmex does alone.

The challengers do not compete on the differential. They compete on the purchase decision — a haematology analyser bought alongside a chemistry line, on a single track, under one contract, is a haematology analyser Sysmex did not sell. That is why Danaher and Abbott, neither of which leads the field technically, hold 24.8% of it between them. Beckman Coulter’s 2025 performance describes the mechanism precisely: mid-single-digit core growth globally, high-single-digit in immunoassay, and a sixth consecutive quarter of mid-single-digit or better core growth outside China. Haematology is not sold on its own.

Haemostasis: a leader with a third of the field

Haemostasis is a different structure entirely, and the difference is visible in the arithmetic.

Sysmex claims first place here too, but its own footnote discloses that the ranking “includes sales through alliances” — its instruments reach much of the market under the Siemens Healthineers brand. Its standalone hemostasis revenue, JPY 72,409 million or USD 489 million, is 15.0% of the USD 3,270 million field. That is not a first place on revenue.

Werfen’s attributed USD 1,200 million is 36.7%. On disclosed and attributed revenue, Werfen leads haemostasis and holds barely more than a third of it. Diagnostica Stago — the only pure-play haemostasis company in the world, EUR 550 million, 115 countries — holds 19.0%. The top three hold 70.5% and there is still a visible fourth tier.

Why the two structures produce two growth rates

Haematology’s near-monopoly makes it the ideal procurement target and a poor growth market: 3.31% against haemostasis’s 5.42%. A field with one dominant vendor, a fixed panel and no upgrade path can only be priced. A field with three substantial vendors, an expanding menu and clinically differentiated assays can still be sold.

The clearest statement of that came from the domestic challenger, not an incumbent. Mindray names immunoassay, clinical chemistry and coagulation — not haematology — as the three core businesses in which it intends to double domestic market share within three years. That target is only achievable in a market where share is still contestable, and it is only attractive in a market where price has just been reset in favour of domestic scale.

The competitive conclusion is uncomfortable for the incumbents. Consolidation did not protect this discipline from administered pricing; it made it the target. The two fields that grew fastest in 2025 are the two with the most competitors.

Value Chain

Value Chain and Revenue Model

This discipline runs on a razor-and-blade model in its purest form, and the ratio is disclosed rather than inferred: reagents, controls and calibrators are 66.8% of market value in 2025, rising to 68.9% by 2033. Instruments are 20.9%, falling to 19.0%. Everything else in the value chain — service, middleware, calibration, accreditation support — is small in revenue and large in lock-in.

Upstream

Both fields depend on a narrow upstream. Coagulation reagents require purified coagulation factors, phospholipid preparations, synthetic chromogenic substrates and — for the latex-based immunoassays behind D-dimer and von Willebrand testing — antibody-coated particles manufactured to a controlled size distribution. Haematology reagents are comparatively simple chemistry — diluents, lytic reagents, stains, sheath fluid — but the controls and calibrators that make a result defensible are not, and they are the part of the chain that cannot be reverse-engineered from a published formulation.

The strategic consequence: upstream concentration is low in haematology and moderate in haemostasis, but the value sits in the validated combination of reagent, instrument and algorithm, which is proprietary and not procurable separately. Werfen’s own description of its model is explicit about where the margin comes from — capital sales of analysers driving “an installed base of recurring high-margin reagent and consumable revenue.”

Instruments, placement and the placement decision

An analyser is placed, not sold in the ordinary sense. Placement economics turn on throughput: a five-part differential analyser in a 200-bed hospital runs a few dozen samples a day; the same platform in a reference laboratory runs a thousand. The reagent annuity scales with the second number, while the placement cost is roughly the same. This is why the discipline’s growth is concentrated in commercial and reference laboratories — 4.75% CAGR against the hospital central laboratory’s 4.09% — and why track automation exists at all: a track converts several analysers into one purchase decision, and one purchase decision is a smaller number for a procurement officer to negotiate against.

Werfen’s 2025 North American launch of the ACL TOP Family 70 Series is the cleanest illustration of where instrument competition has moved. The differentiator it led with was not analytical sensitivity. It was that performance verification studies which “today involve a five-step manual process, are reduced to a two-step automated process,” with centralised QC across a laboratory network. The instrument is being sold as a labour-cost reduction, because the assay itself is no longer the differentiator.

The reagent annuity, and why a tender cuts the business not the invoice

The reason a 40% reagent reduction is catastrophic to the vendor and almost invisible to the hospital is the same reason: reagents are 66.8% of market value but a small share of the cost of an episode of care. A complete blood count reimbursed at USD 6.89 does not become materially cheaper to deliver because the reagent cost falls; the hospital captures the difference only if the fee falls less than the price. In China, the fee fell with it. In the United States, the fee falls on a statutory schedule that has nothing to do with what the laboratory pays.

Distribution and the two go-to-market structures

The discipline is sold through two structurally different channels, and which one dominates a geography predicts the price level better than GDP does. In North America, Western Europe and Japan, the majors sell direct: Werfen operates directly in more than 30 countries; Sysmex runs a regional headquarters structure — Headquarters, Americas RHQ, EMEA RHQ, China RHQ and AP RHQ — rather than a single global P&L, which is precisely why its Chinese deterioration is separately visible. Elsewhere, distribution dominates: Werfen reaches over 100 territories through distributors, and the distributor margin is a permanent wedge between the ex-factory price and the laboratory’s price.

That structure explains a pattern in the regional table. Sysmex’s Americas revenue grew 6.2% and EMEA 12.6% while group sales fell 1.7%; Werfen grew 8% in North America and 7% in EEMEA while Asia-Pacific fell 10.9%. Direct-channel markets held price. The markets that did not were either administered or intermediated.

Margin structure, and what the discipline can and cannot absorb

Sysmex reports the discipline’s margin mechanics better than anyone. Gross profit fell from JPY 271,977 million to JPY 255,681 million on a 1.7% sales decline; SG&A rose 9.0% to JPY 164,351 million; R&D fell 7.3% to JPY 29,162 million; and an impairment loss of JPY 11,557 million was booked against the prior year’s JPY 3,211 million. Operating margin went from 17.2% to 10.4%.

Two of those lines matter more than the rest. SG&A is largely fixed — field service engineers, application specialists, the people who install and validate an analyser — and it does not flex with price. R&D was cut, which is what a company does when it believes the constraint is price rather than technology. A discipline whose leader cuts R&D by 7.3% in the year its market is repriced has told you where it thinks the next dollar of return sits. Werfen, growing 6% outside Asia, did the opposite: EUR 190 million of R&D, up 8%, at 9% of sales, alongside a near-10,000 m² expansion of its Bedford technology centre.

Investment Activity

Investment Activity

Ownership in this discipline changed more in the last three years than in the previous fifteen, and the pattern of change is diagnostic: capital is buying haemostasis, and it is leaving haematology to the incumbents.

The Stago transaction

In April 2026, ARCHIMED Diagnostics — the diagnostics arm of the healthcare private-equity specialist — acquired Diagnostica Stago alongside La Caisse, from the founding Viret family, through a mix of equity and unitranche debt. Stago’s leadership took a minority stake.

Stago is the only pure-play haemostasis company in the world. Founded in 1945, based in Asnières-sur-Seine, it sells in 115 countries and reported revenue of EUR 550 million in 2025. It has been held by the founding family for its entire existence until this transaction.

What the deal reveals is the value placed on a menu rather than a platform. A pure-play haemostasis company with EUR 550 million of revenue and no chemistry, no immunoassay and no molecular business commanded a controlling transaction from a specialist healthcare fund with a dedicated diagnostics vehicle. No comparable pure-play haematology company exists to be acquired — the haematology field is owned inside diversified core-lab portfolios, and there is nothing to buy.

Werfen: the pure-play construction

Werfen has spent four years assembling exactly the position ARCHIMED has now bought into at Stago. It acquired Immucor for approximately USD 2 billion in March 2023, adding transfusion diagnostics; it acquired Omixon in October 2024, adding NGS-based HLA typing; and in July 2024 it divested its Medical Devices business as non-strategic, so that its 2025 figures reflect in vitro diagnostics exclusively.

The result is a company with EUR 2,131 million of sales, EUR 473 million of EBITDA — a 22.2% margin — and EUR 190 million of R&D at 9% of sales, up 8% year on year. It also expanded its Bedford, Massachusetts technology centre by nearly 10,000 m² of R&D and manufacturing space and moved to a new logistics hub in Devens. That is a company converting a portfolio into a platform and building capacity behind it.

The other side of the ledger

The incumbents in haematology are not buying. They are rationalising.

Sysmex booked a JPY 11,557 million impairment loss in the year to March 2026 — up from JPY 3,211 million — that it attributes to changes in the business environment and revisions to strategy, and cut R&D by 7.3%. It completed a new production site in India in August 2024, which is capacity investment in a growth geography rather than portfolio investment.

Danaher is deploying capital in diagnostics but into immunoassay menus, notably the DxI 9000 platform and neurodegenerative disease assays at Beckman Coulter, rather than into haematology.

Abbott reported Diagnostics sales of USD 8,937 million for 2025 — US 3,535, international 5,402 — with US diagnostics down 7.7% and international down 2.0%. Its capital allocation is pointed at Exact Sciences and cancer diagnostics, and at electrophysiology, not at differentials.

What capital intensity means here

Capital intensity in this discipline is high and it is not the instrument. It is reagent manufacturing: controlled-environment filling, lot-to-lot biological validation, calibration traceability and stability programmes. A coagulation reagent line cannot be qualified in a quarter, and a haematology control material that drifts between lots destroys the reference intervals built on it. That is the barrier — not the analyser, which contract manufacturers can build — and it is why the residual in this discipline is 12.72% and not 51%.

It also explains the shape of the investment. Buying a reagent franchise (Stago) buys validated manufacturing and a menu; buying an instrument company buys a placement channel. The market is paying for the first and not the second.

Technology & Innovation

Technology and Innovation

This is a mature discipline, and the maturity is not evenly distributed across its two halves. Haematology’s core measurement has not changed in substance for two decades; haemostasis has added genuine new clinical content in the same period. That asymmetry, not any single product launch, is why one field grows 3.31% and the other 5.42%.

Haematology: three measurement principles, one output

An automated differential combines impedance counting — cells sized by the voltage pulse they produce crossing an aperture — with flow cytometry, where cells pass a laser and are classified by forward and side scatter, frequently with a nucleic-acid or peroxidase stain adding a third axis. The output is a five- or six-part differential plus reticulocyte indices, reported against reference intervals validated for that platform.

Every element of that description is mature. What has changed is at the edges: body-fluid modes that let the same analyser count nucleated cells in cerebrospinal or pleural fluid; low-throughput cartridge platforms that put a three-part differential in a clinic; and digital morphology, where a slide is scanned and pre-classified and a haematologist confirms abnormal cells on a screen. Sysmex distributes its digital morphology capability through an alliance with CellaVision rather than developing it in-house — the same alliance logic that governs its haemostasis distribution.

The honest assessment is that there is no step-change available in the complete blood count. The measurement is at the limit of what a routine laboratory needs, the panel cannot be expanded without becoming a different test, and the clinical decision it informs — is this patient anaemic, infected, bleeding, or harbouring a haematological malignancy — has not changed. Innovation in this half is workflow innovation: throughput, walk-away time, autoverification rates, and the labour arithmetic behind them.

Haemostasis: where the new content is

Coagulation is where the discipline still generates new billable tests, and four clusters account for most of it.

Direct oral anticoagulant monitoring. Anti-Xa and anti-IIa chromogenic assays exist because a growing patient population is on apixaban, rivaroxaban or dabigatran and the old PT/INR does not measure them. Every patient on a DOAC is a patient for whom a routine coagulation screen is uninformative, which converts a monitoring question into a test-menu question.

D-dimer and fibrin degradation products. The assay moved from a rule-out adjunct in venous thromboembolism to a component of diagnostic algorithms across emergency medicine, and its volume tracks guideline proliferation rather than disease incidence.

Thrombophilia and specialised factor testing. Antithrombin, protein C and S, factor assays, von Willebrand antigen and activity, heparin-induced thrombocytopenia, antiphospholipid antibodies. Low volume, high price, difficult to standardise, and resistant to commoditisation because interpretation is part of the product.

Viscoelastic testing. ROTEM and TEG measure clot formation and lysis in whole blood under shear, producing a trace rather than an endpoint. The clinical proposition is patient blood management: transfuse on evidence of coagulopathy rather than on a protocol, and reduce blood product spend. It is the one haemostasis technology that has genuinely moved testing out of the central laboratory and into the operating room and emergency department, and it is the main reason point-of-care haemostasis holds 9.1% of the discipline and grows to 9.6%.

Where the innovation money is going, and what it implies

The allocation is visible in the two leaders’ disclosures and it points the same way. Werfen spent EUR 190 million on R&D, up 8%, and expanded manufacturing and R&D capacity in Bedford, Massachusetts. Sysmex cut R&D 7.3% to JPY 29,162 million while booking an impairment loss of JPY 11,557 million “associated with changes in the business environment and revisions to strategy.”

Read together, those two lines say something specific: the field with menu headroom is being funded, and the field without it is being rationalised. That is consistent with the forecast. It is not consistent with the assumption, common in this sector, that consolidation funds innovation. Here the consolidated field is the one cutting.

Market Risk

Market Risk

This discipline has one dominant risk and several secondary ones, and the ordering is not ambiguous. The forecast’s sensitivity band is 56 basis points either side of base across all scenarios, and almost all of that width comes from a single variable: whether two governments continue to cut administered prices.

1. Administered price risk — high

Two documents, both already published, set the discipline’s price for the forecast window. The preliminary CY 2027 Medicare fee schedule cuts the complete blood count 11.3% and 1,171 of 1,528 priced codes; the phase-in cap of 15% a year through 2029 defers rather than prevents the deeper reductions, with 775 tests taking the full 15% in year one. China’s provincial alliances have demonstrated that a 40% reduction on coagulation reagents is achievable and repeatable.

The exposure is asymmetric because the mechanism is not competitive. A vendor cannot respond to a statutory fee reduction by winning share from a competitor who faces the same reduction. It can only reduce cost, exit the geography, or accept a lower margin. Sysmex did all three in one year: margin from 17.2% to 10.4%, China down 24.2%, R&D down 7.3%.

2. China policy risk — high

China is 11.81% of the market in this report’s regional split, and the single largest source of variance. The 2025 disclosures are consistent across every vendor that reports by geography: Sysmex China −24.2%, with segment profit down 12.2% despite lower SG&A; Werfen Asia-Pacific −10.9% against 6% organic growth elsewhere; Mindray domestic −22.97% against international +7.40%.

Mindray’s own account is the most useful, because it describes the mechanism from inside: policy has “effectively standardised diagnosis and treatment behaviour, improved the efficiency of medical insurance payments,” and in vitro diagnostics has entered “a period of adjustment and contraction, with both reagent volume and price declining to varying degrees.” It then states that industry concentration and import substitution are accelerating — and that its own IVD market share grew.

That is the risk in one sentence. Chinese policy is not destroying the market; it is redistributing it, and the redistribution favours domestic vendors. For a Western incumbent, the downside case is not a smaller Chinese market but a smaller Chinese market share of a market that is itself smaller.

3. Concentration and customer risk — moderate

With 87.28% of value attributed to ten vendors and the top three holding most of it, the discipline’s revenue is concentrated in a handful of P&Ls. Conversely, the vendors face concentrated buyers: consolidated reference laboratory networks and group purchasing organisations negotiate as single entities, and a track decision can move a multi-year reagent annuity in one meeting.

4. Substitution and setting migration — moderate

Two substitutions are underway and neither is existential. Viscoelastic and whole-blood coagulation testing moves volume from the central laboratory to the operating room and emergency department — same clinical question, different invoice and different margin. Molecular haematology moves some content out of the discipline entirely: BCR-ABL monitoring, JAK2 and NPM1 testing belong to the molecular cluster, and as those assays become routine they remove high-value content from the haematology menu rather than adding to it.

5. Geopolitical and tariff exposure — high at the margin

Werfen names it directly: tariff policies applied by the United States had a global impact, generating reciprocal responses from various markets, especially China, and this “has had a direct effect on the company’s operating result.” Reagent manufacturing is geographically concentrated and biologically validated per site, which means a tariff or a supply disruption cannot be resolved by switching production without requalification.

6. Foreign exchange — moderate

Sysmex discloses the magnitude plainly: foreign exchange added JPY 15.48 billion to sales and JPY 8.56 billion to operating profit in the year to March 2025. A discipline whose leaders report in yen and euro and sell in dollars and renminbi carries a translation exposure that can exceed the underlying growth rate in any single year.

What would move the forecast

Only two things, at scale. A decision by CMS to reduce rates by less than the statutory maximum — which the statute permits and ACLA has formally requested — would lift the United States path by low single-digit percentages. A decision by China’s provincial alliances to extend coagulation procurement to haematology reagent bundles would take the downside case below USD 10,180 million. Everything else in this report moves the number by less than the rounding.

Regulatory Landscape

Regulatory Landscape

Haematology and coagulation diagnostics sit in the most heavily regulated part of the IVD world, and the regulatory burden is not uniform across the two fields. A routine complete blood count and a von Willebrand factor activity assay are both in vitro diagnostic tests and share almost nothing else in their approval pathway.

European Union — IVDR

Under Regulation (EU) 2017/746, most coagulation assays classify above the lowest risk band, and specialised assays — thrombophilia, heparin-induced thrombocytopenia, viral marker-adjacent donor testing — sit higher still. Higher classification requires notified body involvement, and notified body capacity has been the binding constraint across the transition. For a vendor, that means an instrument placement decision now has a regulatory timeline attached that it did not have under the previous directive, and menu expansion carries per-assay conformity assessment cost.

The practical effect on competition is to advantage scale. A vendor with an established notified body relationship and a large installed base amortises conformity assessment across more revenue than a challenger does. That reinforces the concentration this report measures — but it also raises the fixed cost of holding a broad menu, which is part of why the residual in haemostasis is larger than in haematology.

United States — FDA and CLIA

Analysers and assays reach the market through the 510(k) pathway with a substantial-equivalence predicate, and the instrument and its reagent menu are cleared together — which is the regulatory expression of the closed-system economics described earlier. Werfen’s ACL TOP Family 70 Series reached North America in March 2025 following 510(k) clearance and Health Canada licensure, and that sequencing is typical: one platform, two jurisdictions, cleared before or alongside commercial launch.

CLIA complexity categorisation determines who may run the test and therefore where it can be placed. Most automated haematology sits in the moderate-complexity band; whole-blood point-of-care haemostasis is often waived or moderate, which is what allows it into the operating room. The regulatory decision and the setting decision are the same decision.

China — NMPA registration plus procurement as a price instrument

China is the one jurisdiction in this report where the price mechanism is a regulatory instrument. Registration through the National Medical Products Administration is a conventional approval process; the provincial procurement platform is where the price is actually set. Anhui’s 2023 coagulation procurement worked by requiring bidders to self-declare onto a provincial list, setting the ceiling at the volume-weighted average of the previous year’s platform prices, and committing 90% of prior-year volume to the winners. Registration admits a product; platform listing and tender award determine whether it sells and at what price.

This has an implication for Western vendors that is often missed. Being registered in China no longer implies being able to sell at a defensible price. The vendor that does not win a provincial award loses the committed volume, and the volume committed is 90% of the market that mattered.

Japan — PMDA and a fee schedule that has already absorbed its cuts

Japan operates a national reimbursement structure under which laboratory test pricing is revised on a scheduled cycle. The consequence is visible in this report’s regional table: Japan grows at 2.22%, the slowest of any region, and Sysmex’s domestic sales fell 13.5% to JPY 58,603 million with the domestic sales ratio down 1.6 points to 11.7%. The cuts have largely happened; what remains is a mature market with a shrinking population.

Technical standards, and why they matter commercially

Traceability in coagulation is not a formality. Reference preparations, calibration hierarchies and lot-to-lot validation underpin whether two laboratories reporting the same INR are reporting the same thing, and the standards bodies — CLSI in particular, alongside WHO international standards for thromboplastin and factor concentrates — define the hierarchy that makes that possible. ISO 15189 accreditation then requires the laboratory to demonstrate it.

Commercially, this is the moat behind the moat. A laboratory cannot change reagent supplier without revalidating the reference intervals and, for coagulation, re-establishing local calibration against the international standard. The switching cost is not contractual; it is scientific.

The regulatory conclusion

In every major jurisdiction the approval pathway is becoming more expensive and the price mechanism is becoming more administered. Those two movements compress from opposite ends, and they explain a pattern this report measures but does not create: haematology, where the menu is fixed and the approval burden per revenue dollar is highest, is the field that is being rationalised; haemostasis, where new assays justify new approvals, is the field still being funded.